Time in Range complements A1C and provides actionable information.
The consensus data recommend that patients with T1D or T2D spend >70% of their time in range (3.9–10.0 mmol/L).6
Public and private reimbursement is available for the FreeStyle Libre system.
Resources and information for every stage of your experience with FreeStyle Libre.
T1D=type 1 diabetes; T2D=type 2 diabetes.
* Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal-use sensor-based glucose monitoring systems.
† Data collected from the FreeStyle Libre System. FreeStyle Libre 2 has the same features as the FreeStyle Libre System, with the addition of optional real-time glucose alarms. Study data are applicable to both products.
‡ The LibreView website is only compatible with certain operating systems and browsers. Please check www.libreview.com for additional information.
§ The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Finger pricks are required if readings do not match symptoms or expectations. The FreeStyle Libre 2 sensor communicates with the FreeStyle Libre 2 reader that started it or the FreeStyle Libre 2 app that started it. The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle Libre 2 requires registration with LibreView.
¶ Finger pricks are required if your glucose readings and alarms do not match symptoms or expectations.
1. Data on file, Abbott Diabetes Care.
2. Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388(10057):2254-63.
3. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73.
4. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Symposium presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
5. Seibold A, et al. A meta-analysis of real-world observational studies on the impact of flash glucose monitoring on glycemic control as measured by A1C. Poster presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
6. Battelino T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42(8):1593-603.
7. Kröger J, et al. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes [published online ahead of print December 12, 2019]. Diabetes Ther 2019. https://doi.org/10.1007/s13300-019-00741-9.
This site is intended for Healthcare Professionals only. Visit patient site.
The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in adults aged 18 years and older with diabetes mellitus. Always read and follow the label/insert.
The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.
You are now being redirected to a third-party website not under the control of Abbott. Abbott is not responsible for the contents of such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site by Abbott.
Do you wish to leave this site?